Patient demographic and baseline characteristics in the renal analysis.

<p>Patient demographic and baseline characteristics in the renal analysis.</p

Univariate IRRs (95% CI) for risk factors for fracture among patients prescribed single-tablet regimens.

<p>Bold typeface indicates that the CI does not cross unity. CI: confidence interval; IRR: incidence rate ratio. *Defined as at least 60 days of cumulative exposure within an 18-month period.</p

Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens

<div><p>Objectives</p><p>Tenofovir disoproxil fumarate (TDF)-containing antiretroviral regimens have been associated with an increased incidence of renal and bone adverse outcomes. Here, we estimated the real-world incidence of renal and bone adverse outcomes among patients with HIV infection receiving different TDF-containing single-tablet regimens (STRs).</p><p>Methods</p><p>This cohort study used US health insurance data spanning the years 2008–2014. We identified HIV-infected patients aged ≥18 years (all HIV patients) and those with ≥6 months of continuous enrollment prior to initiating efavirenz/emtricitabine/TDF (EFV/FTC/TDF), rilpivirine/FTC/TDF (RPV/FTC/TDF) or elvitegravir/cobicistat/FTC/TDF (EVG/COBI/FTC/TDF). Renal adverse outcomes were identified using renal International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes. Bone adverse outcomes were identified using ICD-9-CM diagnosis codes for fracture. Incidence rates (IRs) and associated 95% confidence intervals (CIs) were estimated assuming a Poisson distribution, and outcomes between STRs were compared using IR ratios (IRRs) and IR differences (IRDs).</p><p>Results</p><p>We identified 9876 and 10,383 eligible patients for the renal and fracture analyses, respectively. Observed IRs for renal adverse outcomes were 9.7, 10.5, 13.6, and 18.0 per 1000 person-years among those receiving EFV/FTC/TDF, RPV/FTC/TDF, or EVG/COBI/FTC/TDF, or all HIV patients, respectively. Corresponding values for IRs of fracture were 3.4, 3.6, 7.2, and 4.4 per 1000 person-years, respectively. Renal adverse outcomes with EFV/FTC/TDF were significantly less frequent than with EVG/COBI/FTC/TDF (IRD −3.96; 95% CI: −7.31, −1.06). No IRR differences were identified for the renal analysis. Fractures with EFV/FTC/TDF were significantly less frequent than with EVG/COBI/FTC/TDF (IRR 0.47; 95% CI: 0.27, 0.81 and IRD −3.85; 95% CI: −5.02, −2.78).</p><p>Conclusions</p><p>In this large real-world database, observed IRs for renal adverse outcomes with TDF-containing STRs were lower or similar to those for all HIV patients, with the lowest IRs observed among patients receiving EFV/FTC/TDF. Compared with all HIV patients, the observed IR for fracture was higher with EVG/COBI/FTC/TDF, comparable with RPV/FTC/TDF, and lower with EFV/FTC/TDF.</p></div

Incidence rates for fracture by STR.

<p>Incidence rates for fracture by STR.</p

Patient demographic and baseline characteristics in the fracture analysis.

<p>Patient demographic and baseline characteristics in the fracture analysis.</p

Incidence rates for renal adverse outcomes by STR.

<p>Incidence rates for renal adverse outcomes by STR.</p

Univariate and multivariate adjusted IRRs (95% CI) for risk factors for renal adverse outcomes among patients prescribed STRs.

<p>*Including adjustment for EFV/FTC/TDF vs. RPV/FTC/TDF. †Including adjustment for EFV/FTC/TDF vs. EVG/COBI/FTC/TDF. Calendar year was not included as a covariate owing to strong collinearity with STR use. Bold typeface indicates that the CI does not cross unity. CI: confidence interval; EFV/FTC/TDF: efavirenz/emtricitabine/tenofovir disoproxil fumarate; EVG/COBI/FTC/TDF: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; IRR: incidence rate ratio; RPV/FTC/TDF: rilpivirine/emtricitabine/tenofovir disoproxil fumarate; STR: single-tablet regimen.</p